1. Home
  2. MTLS vs ENTA Comparison

MTLS vs ENTA Comparison

Compare MTLS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$7.02

Market Cap

387.8M

Sector

Technology

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.60

Market Cap

378.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTLS
ENTA
Founded
1990
1995
Country
Belgium
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
387.8M
378.0M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
MTLS
ENTA
Price
$7.02
$13.60
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.40
AVG Volume (30 Days)
80.0K
195.9K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
$6.38
$7.76
Revenue Next Year
$6.45
N/A
P/E Ratio
$61.39
N/A
Revenue Growth
N/A
16.48
52 Week Low
$4.78
$7.05
52 Week High
$7.50
$17.15

Technical Indicators

Market Signals
Indicator
MTLS
ENTA
Relative Strength Index (RSI) 63.31 50.26
Support Level $6.36 $13.47
Resistance Level $7.50 $13.98
Average True Range (ATR) 0.21 0.67
MACD 0.06 0.05
Stochastic Oscillator 80.58 36.99

Price Performance

Historical Comparison
MTLS
ENTA

About MTLS Materialise NV

Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: